Not who develops heart failure — this is about people who already have it, and what separates a stable course from one that ends sooner in death or a hospital admission for it. A study of over 50,000 people with established heart failure found that higher body mass index causally worsens that course, and built its own genetic map of the outcome to prove it.
Heart failure is a chronic condition in which the heart cannot pump blood as well as the body needs. Most of this site's cardiovascular pages ask who develops a disease. This page asks a different, later question: among people who already have heart failure, what separates those whose disease stays stable from those who die of it, or are hospitalised for it, sooner.
The study behind this page pooled 50,636 people with established heart failure from 22 cohorts — 12 heart failure trials, a prospective case-cohort study, nine cohorts nested inside broader cardiovascular trials, and one population-based cohort from the UK Biobank, all of European ancestry. Over a median follow-up of 27.0 months, all-cause mortality occurred in 23% of patients and the composite endpoint — cardiovascular death or heart failure hospitalisation — occurred in 22%.
Its main question was about body mass index (BMI). Excess weight is strongly associated with developing heart failure in the first place, but whether it worsens the course of heart failure someone already has was less settled — and association alone cannot answer whether BMI is a cause of worse outcomes or just travels alongside one. The study used Mendelian randomization: because a person's genetically predicted BMI is set at conception, before heart failure develops, an association between that genetic prediction and later outcomes is much harder to explain by reverse causation or confounding than an association with measured BMI would be.
The answer was clear. Genetically predicted BMI was associated with a higher rate of all-cause mortality (hazard ratio 1.21 per 4.8-unit increase in BMI, 95% CI 1.13–1.29) and of the composite of cardiovascular death or heart failure hospitalisation (hazard ratio 1.29, 95% CI 1.20–1.38) — and the pattern held whether ejection fraction was reduced or preserved.
To run that Mendelian randomization analysis, the study first needed its own genome-wide association study of the outcome — the composite of cardiovascular death or heart failure hospitalisation — across all 50,636 patients, so that genetic associations with BMI could be compared against genetic associations with the outcome. rs62576378, near EPB41L4B, comes from that outcome-side genome-wide scan.
The paper's own reported results are about the BMI finding as a whole, not about this individual locus by name — it does not offer a mechanism for why the EPB41L4B region associates with faster or slower progression. This page says that plainly rather than writing in a mechanism the paper does not provide. What the variant represents honestly is a real signal from a real, very large outcome GWAS, built as a tool inside a larger causal question about weight.
This page applies to people who already have a diagnosis of heart failure. It has nothing to say about who develops heart failure in the first place — that is a different, earlier question, and a different genetics.
What actually manages this risk. The study's own conclusion is that its findings "support the potential role of weight-management strategies across the ejection fraction spectrum" in people who already have heart failure. Whether and how to manage weight is a conversation with a cardiologist, who weighs it alongside medication, device therapy and the specific type of heart failure involved — not something this or any single genotype decides.
The cardiovascular disease risk factors page covers the genetics of developing cardiovascular disease in the first place — the earlier question this page deliberately sets aside.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Heart Failure Progression comes down to these specific, well-studied positions — not a diagnosis.
EPB41L4B · rs62576378
See detailed info →Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Heart Failure Progression. MyGeneLog™. https://www.mygenelog.com/conditions/heart-failure-progression
No. This page is about people who already have heart failure, and what predicts a faster or slower course from there — death, or hospitalisation for it. It says nothing about who develops heart failure in the first place.
Using a method called Mendelian randomization, it found that genetically predicted body mass index causally worsens outcomes in people with established heart failure — a higher rate of death and of cardiovascular death or heart failure hospitalisation — regardless of whether ejection fraction was reduced or preserved.
The paper does not say. It comes from the study's own genome-wide scan of heart failure outcomes, built as a tool to test the BMI question, and the published results describe the BMI finding as a whole rather than this locus on its own.
That is a conversation for a cardiologist, not a genotype. The study supports weight management as a general strategy in heart failure care across the ejection-fraction spectrum — it does not say any specific genotype should change an individual's plan.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.